The U.S. Supreme Court has agreed to consider yet another patent case. The case involves the burden of proof required when a license holder is accused of patent infringement.
In Medlmmune, Inc. v. Genentech, Inc., 549 U.S. 118, 137 (2007), the Supreme Court ruled that a patent licensee that believes that its products do not infringe the patent and accordingly are not subject to royalty payments is “not required … to break or terminate its … license agreement before seeking a declaratory judgment in federal court that the underlying patent is … not infringed.”
The question presented in the current Supreme Court case, Medtronic, Inc. v. Boston Scientific Corp., is whether the licensee has the burden to prove that its products do not infringe the patent when filing a declaratory action. Medtronic licenses defibrillator patents controlled by Boston Scientific and challenged that its new products did not infringe those patents.
View original post 189 more words